Oncologi, Inc., a biotechnology company developing next-generation RNA-based cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has granted a U.S.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果